BSE: 531043
DHANVANTRI JEEVAN REKHA LTD.
Operates Dhanvantri Hospital, a NABH-certified healthcare facility in Meerut, Uttar Pradesh, providing hospital services such as inpatient, outpatient and diagnostic care to patients in the region. For FY26, total income stood at Rs 25.86 crore with a net profit of Rs 0.4 crore. The cost structure is led by other operating expenses at 50.7% of revenue, followed by materials at 25.6% — covering pharmaceuticals and medical consumables — and employee costs at 20.5%, paying for doctors, nurses and support staff. The hospital is debt-free with cash and bank balances of Rs 353 lakh as of March 2026, against current liabilities of Rs 550 lakh. Quarterly results have been uneven, with the company swinging between profit and loss across individual FY26 quarters. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Hospital services. Small, single-asset, service-oriented hospital business
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 17 | 18 | 20 | 23 | 26 |
| EBITDA (ex other income) | 1 | 1 | 1 | 1 | 1 |
| margin % | 8.9 | 3.3 | 4.1 | 3.2 | 3.0 |
| Owners' profit | 0 | (0) | 0 | 1 | 0 |
| EPS, as reported (₹) | 1.20 | (0.53) | 0.42 | 1.60 | 0.94 |
| ROE % · ROCE % | 5.1 · 5.7 | (2.3) · (1.3) | 1.7 · 2.3 | 5.0 · 4.9 | 3.8 · 3.4 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 1 | (0) | 3 | (0) | 2 |
| Capex | (0) | (1) | (0) | (1) | (1) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5 | 6 | 6 | 6 | 11 | 7 | 7 | 8 |
| Profit before tax | 0 | 0 | 0 | 0 | (0) | 0 | 0 | 0 |
| Net profit | 0 | 0 | 0 | 0 | (0) | 0 | 0 | 0 |
| EPS (₹) | 0.40 | 0.36 | 0.45 | 0.15 | (0.19) | 0.41 | 0.72 | 0.44 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 32,213 | 46.3 | 12.68 | 37.5 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 14,838 | 79.1 | 15.50 | 41.4 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 11,341 | 23.4 | 7.44 | 27.1 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 7,871 | 28.9 | 13.43 | 28.7 | 27.8 | 33.2 | 10.9 | 33.9 |
| NEPHROCARE HEALTH SERV L | 6,301 | 65.1 | 5.64 | 24.9 | 6.9 | 8.6 | — | 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,628 | 16.7 | 1.66 | 8.3 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,621 | 45.3 | 6.66 | 16.4 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,170 | 19.5 | 3.53 | 13.8 | 18.1 | 22.5 | (8.9) | 52.6 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 15.9 | 23.4 | 7 of 25 | 75% |
| P/B | 0.9 | 2.0 | 5 of 24 | 83% |
| ROCE | 3.3 | 6.1 | 18 of 29 | 39% |
| ROE | 3.8 | 6.0 | 15 of 24 | 39% |
| Debt / Equity | 0.0 | 0.1 | 1 of 23 | 77% |
| EBITDA margin | 4.7 | 25.6 | 19 of 24 | 22% |
| Revenue growth | 41.6 | 20.8 | 7 of 25 | 75% |
| Profit growth | 200.0 | 22.0 | 2 of 25 | 96% |
| Market cap | 9 | 34 | 24 of 30 | 21% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 15 Oct 2026 · RTA compliance certificate under Regulation 74(5) for Sep 2026 quarter | compliance | minimal | — | — |
| 1 Oct 2026 · Trading window closed from Oct 1 for Sept quarter results | compliance | minimal | — | — |
| 29 Sept 2026 · Proceedings of 33rd AGM held on 29 September 2026 | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Revised Annual Report FY26 filed; corrigendum issued for errors | investor communications | medium | — | — |
| 5 Sept 2026 · 33rd AGM Notice published in newspapers with e-voting and book closure details | compliance | minimal | — | — |
| 5 Sept 2026 · FY26 Annual Report: Revenue up 14%, PAT declines to Rs 39 lakh | results | medium | — | — |
| 4 Sept 2026 · 33rd AGM on 29 Sept 2026 at 3 PM via video conferencing | board shareholder meetings | low | — | — |
| 29 Aug 2026 · Newspaper notice for 33rd AGM and email update | compliance | minimal | — | — |
| 27 Aug 2026 · Book Closure and E-voting details for 33rd AGM on 29 Sep 2026 | board shareholder meetings | low | — | — |
| 27 Aug 2026 · Book closure for 33rd AGM from September 23 to 29, 2026 | corporate actions | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.